文献速递皮肤肿瘤

T1a期皮肤恶性黑色素瘤患者的前哨淋巴结活检:一项多中心队列研究

Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study.
PubMed 文献 · J Am Acad Dermatol · 2022-09-30

该多中心队列研究纳入2001至2020年间5个高容量黑色素瘤中心的965例病理T1a期(<0.80 mm、无溃疡)皮肤黑色素瘤患者,分析前哨淋巴结阳性(SLN+)的相关因素。总体SLN+率为4.4%(N=43),年龄≤42岁、头颈部原发、淋巴血管侵犯及≥2个核分裂/mm²与SLN+相关;年龄<42岁且≥2个核分裂/mm²者SLN+率为18.4%。

要点

  • T1a期黑色素瘤患者总体前哨淋巴结阳性率为4.4%(43/965)。
  • 年龄≤42岁、头颈部原发、淋巴血管侵犯、≥2个核分裂/mm²与SLN+相关。
  • 年龄<42岁且≥2个核分裂/mm²者SLN+率为18.4%。

核心结论

  • T1a期黑色素瘤患者SLN+率低,但年轻年龄、淋巴血管侵犯、核分裂活性及头颈部原发部位似乎与SLN+风险升高相关。

研究设计与样本

  • 多中心队列研究,纳入2001至2020年间5个高容量黑色素瘤中心的965例病理T1a期(<0.80 mm、无溃疡)皮肤黑色素瘤患者,均接受广泛局部切除加前哨淋巴结活检。
  • 采用单因素和多因素逻辑回归分析患者及肿瘤特征与SLN+的关联。
  • 年龄以≤42岁(25%四分位切点)和>42岁二分类。

主要发现

  • 965例患者中总体SLN+率为4.4%(N=43)。
  • 年龄≤42岁者SLN+率7.5% vs 年龄>42岁者3.7%(OR 2.14;P=0.03)。
  • 头颈部原发肿瘤者SLN+率9.2% vs 其他部位4%(OR 2.75;P=0.04)。
  • 有淋巴血管侵犯者SLN+率21.4% vs 无者4.2%(OR 5.64;P=0.01)。
  • ≥2个核分裂/mm²者SLN+率8.2% vs <2个核分裂/mm²者3.4%(OR 2.31;P=0.03)。

局限性

  • 回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sentinel lymph node biopsy is not routinely recommended for T1a cutaneous melanoma due to the overall low risk of positivity. Prognostic factors for positive sentinel lymph node (SLN+) in this population are poorly characterized. OBJECTIVE: To determine factors associated with SLN+ in patients with T1a melanoma. METHODS: Patients with pathologic T1a (<0.80 mm, nonulcerated) cutaneous melanoma from 5 high-volume melanoma centers from 2001 to 2020 who underwent wide local excision with sentinel lymph node biopsy were included in the study. Patient and tumor characteristics associated with SLN+ were analyzed by univariate and multivariable logistic regression analyses. Age was dichotomized into ≤42 (25% quartile cutoff) and >42 years. RESULTS: Of the 965 patients identified, the overall SLN+ was 4.4% (N = 43). Factors associated with SLN+ were age ≤42 years (7.5% vs 3.7%; odds ratio [OR], 2.14; P = .03), head/neck primary tumor location (9.2% vs 4%; OR, 2.75; P = .04), lymphovascular invasion (21.4% vs 4.2%; OR, 5.64; P = .01), and ≥2 mitoses/mm2 (8.2% vs 3.4%; OR, 2.31; P = .03). Patients <42 years with ≥2 mitoses/mm2 (N = 38) had a SLN+ rate of 18.4%. LIMITATIONS: Retrospective study. CONCLUSION: SLN+ is low in patients with T1a melanomas, but younger age, lymphovascular invasion, mitogenicity, and head/neck primary site appear to confer a higher risk of SLN+.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Shannon AB, Sharon CE, Straker RJ, et al. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. J Am Acad Dermatol. 2022. PMID: 36184008. doi:10.1016/j.jaad.2022.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。